What is LNZAW's health score?

LanzaTech Global, Inc. (LNZAW) has a TradeApes health score of 41 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is LNZAW's estimated fair value?

Based on our 5-year discounted cash flow model, LanzaTech Global, Inc.'s estimated fair value is $20.77 per share, representing a 237.2% upside from the current price. This is a model estimate, not a price target or investment recommendation.

Is LNZAW undervalued or overvalued?

Our model currently rates LNZAW as Undervalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for LNZAW... Refresh in a moment for the full analysis.

LanzaTech Global, Inc. (LNZAW)

Materials Undervalued low weak

Updated: 2026-06-05

TradeApes Score

Financial Strength

40 Weak

Operating Trend

40 Weak

Relative Value

40 Weak

Capital Allocation

40 Weak

Risk

50 Mixed

Est. Fair Value $20.77

DCF Upside +237.2%

Key Findings

+ Low leverage — net debt/EBITDA below 1×

Unlock Full Report →

− Altman Z-Score in distress zone — elevated bankruptcy risk

Unlock Full Report →

Create an account for unlimited access

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.